Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that give hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc., announced today that the two companies have…